Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: HeyRainier who wrote (862)	5/2/1998 7:19:00 AM
From: SnowShredder	Respond to of 4140

Recently I ran into a old friend from high school who is now a broker. He had not heard of SNRS :( when I had asked him. I asked him how they do their DD, and he said that they read reports from various analysts and do little research other than that. He also told me that maybe 30% of the brokers he knows use technical analysis. Based on this I take this hype with a grain of salt. Best of Luck, Where'd He Go?

To: HeyRainier who wrote (862)	5/2/1998 9:57:00 AM
From: Sylvester	Read Replies (1) \| Respond to of 4140

Rainer, I agree with everything your saying and perhaps if I were home during the day, I might have sold out some of my position at 9.5 such as you did. My average buy in is a little below $7. I feel it's safe but I welcome your opinion. I've accumulated my limit for one stock. In my profession, I'm a health care consultant developing marketing and retention programs for insurance companies. Not every policy will cover hyperopia but over 50% will. This creates a problem for more expensive procedures and a great advantage for less costly ones. Much of the speculation about Sunrise has to do with even a small share of the market selecting this procedure versus others. More likely, the reimbursement fee for service policies offer subscribers will be capped at Sunrise's $1000 per eye cost. The patient will pay the balance for alternative procedures. Managed care policies will not even offer a choice. Opthalmologists have already invested a fortune in Beam and Visix (sp?) but the ROI Sunrise offers plus the insurance reimbursement may make that moot. The Sunrise technology is already known to some insurance companies who anxiously await approval for what it will do to their stock prices. I'm certain that fund analysists are aware as well. Aside from those loyalists on this thread, SNRS is largely owned by small investors who await the same dream but will ultimately sell for a small profit if no great move is seen in the short term. History suggests that there is little patience amongst investors who hear a great story, buy a stock and relax for the long term. My conclusion is the story is wrong and you are right. We're being watched by big players and this is important, but they won't tip their hand and drive the price up sharply even after NASDAQ approval. We'll get to the teens and stay there a long while, with greater fluctuation than now but with a strong base at $10. Then, only those with will and courage will reap the true potential of this investment. IMO Regards, Sylvester